UBS Group AG - BROOKLYN IMMUNOTHERAPEUTICS ownership

BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 45 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
UBS Group AG ownership history of BROOKLYN IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2022$3,000
-70.0%
11,646
-37.9%
0.00%
Q2 2022$10,000
-64.3%
18,746
+38.9%
0.00%
Q1 2022$28,000
-58.8%
13,500
-18.3%
0.00%
Q4 2021$68,000
-4.2%
16,530
+118.8%
0.00%
Q3 2021$71,000
+3450.0%
7,554
+1132.3%
0.00%
Q1 2021$2,0006130.00%
Other shareholders
BROOKLYN IMMUNOTHERAPEUTICS shareholders Q2 2022
NameSharesValueWeighting ↓
Cypress Point Wealth Management, LLC 471,878$8,499,0006.04%
BALDWIN BROTHERS LLC/MA 44,116$795,0000.09%
DOWLING & YAHNKE LLC 15,806$285,0000.02%
INVERNESS COUNSEL LLC /NY/ 13,307$240,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 15,000$270,0000.01%
Cutler Group LLC / CA 4,200$75,0000.00%
MetLife Investment Management, LLC 10,805$194,5980.00%
HAP Trading, LLC 13,900$64,0000.00%
METROPOLITAN LIFE INSURANCE CO/NY 8,272$148,9790.00%
Ameritas Investment Partners, Inc. 1,867$34,0000.00%
View complete list of BROOKLYN IMMUNOTHERAPEUTICS shareholders